Abeona Therapeutics (ABEO) EPS Estimated At $-0.12, PetroChina Company Limited (ADR) (PTR) Covered By 4 Bulls

July 25, 2017 - By Dolores Ford

Among 9 analysts covering PetroChina Company Limited (NYSE:PTR), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. PetroChina Company Limited had 16 analyst reports since August 25, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, April 18 by Bank of America. On Monday, August 31 the stock rating was downgraded by Bank of America to “Neutral”. The rating was upgraded by Macquarie Research on Friday, May 5 to “Neutral”. The stock of PetroChina Company Limited (ADR) (NYSE:PTR) has “Hold” rating given on Wednesday, April 5 by HSBC. The rating was downgraded by JP Morgan to “Neutral” on Monday, May 23. The firm has “Underweight” rating given on Tuesday, May 10 by Morgan Stanley. The firm has “Underperform” rating given on Monday, April 10 by Credit Suisse. The firm earned “Buy” rating on Monday, March 21 by Mizuho. The company was upgraded on Thursday, July 6 by Credit Suisse. The stock of PetroChina Company Limited (ADR) (NYSE:PTR) has “Buy” rating given on Wednesday, October 28 by Societe Generale. See PetroChina Company Limited (ADR) (NYSE:PTR) latest ratings:

06/07/2017 Broker: Credit Suisse Old Rating: Underperform New Rating: Neutral Upgrade
05/05/2017 Broker: Macquarie Research Old Rating: Underperform New Rating: Neutral Upgrade
10/04/2017 Broker: Credit Suisse Old Rating: Neutral New Rating: Underperform Downgrade
05/04/2017 Broker: HSBC Old Rating: Reduce New Rating: Hold Downgrade
24/02/2017 Broker: Jefferies Old Rating: Underperform New Rating: Buy Upgrade

Analysts expect Abeona Therapeutics Inc (NASDAQ:ABEO) to report $-0.12 EPS on August, 15.They anticipate $0.08 EPS change or 40.00% from last quarter’s $-0.2 EPS. After having $-0.13 EPS previously, Abeona Therapeutics Inc’s analysts see -7.69% EPS growth. About 575,158 shares traded. Abeona Therapeutics Inc (NASDAQ:ABEO) has risen 151.02% since July 25, 2016 and is uptrending. It has outperformed by 134.32% the S&P500.

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical firm developing novel gene therapies for life-threatening rare genetic diseases. The company has market cap of $338.82 million. The Company’s lead programs include ABO-102 , an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It currently has negative earnings. It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy for rare blood diseases.

Among 6 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics had 11 analyst reports since December 16, 2015 according to SRatingsIntel. H.C. Wainwright maintained Abeona Therapeutics Inc (NASDAQ:ABEO) rating on Wednesday, July 19. H.C. Wainwright has “Buy” rating and $2000 target. The company was reinitiated on Wednesday, April 20 by Rodman & Renshaw. Maxim Group maintained the stock with “Buy” rating in Tuesday, July 18 report. The company was maintained on Thursday, June 1 by Jefferies. The rating was initiated by Maxim Group on Wednesday, December 16 with “Buy”. The stock of Abeona Therapeutics Inc (NASDAQ:ABEO) has “Buy” rating given on Thursday, May 25 by FBR Capital. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, September 8. The firm has “Buy” rating by Cantor Fitzgerald given on Tuesday, July 18. The firm earned “Buy” rating on Friday, January 6 by Jefferies. The stock of Abeona Therapeutics Inc (NASDAQ:ABEO) has “Buy” rating given on Monday, June 5 by Cantor Fitzgerald.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com